VANCOUVER, British Columbia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned
subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that it has
been accepted to present its pre-clinical data on its inflammatory bowel disease (“IBD”) research program for both Colitis and
Crohn’s disease at the upcoming Digestive Disease Week Annual Conference, held in San Diego, CA on May 18th
-21st.
Results of Nash’s recently announced Crohn's study demonstrated significant improvements in multiple
measurements for both NP-120 and NP-178 including:
- Improved body weight, stool consistency, occult positivity, colon length and weight and its ratios
- 5-ASA, the positive control reduced the histopathology severity score by 44.0% (p<0.01)
- NP-120 (30 mg/kg) reduced the histopathology severity score by 45.1% (p<0.01)
- NP-178 (160 mg/kg) reduced the histopathology severity score by 66.8% (p<0.001)
Results of Nash’s recently announced ulcerative colitis study demonstrated significant improvements in multiple
measurements for both NP-120 and NP-178 including:
- Both compounds improved body weight, stool consistency, occult positivity, colon length and weight and its
ratios
- 5-ASA (100 mg/kg), the positive control and standard of care, reduced the histopathology severity score by 83.5%
(p<0.0001)
- NP-120 (30 mg/kg) reduced the histopathology severity score by 81.6% (p<0.0001)
- NP-178 (160 mg/kg) reduced the histopathology severity score by 83.1% (p<0.0001)
The Digestive Disease Week Conference is one of the top 50 medical meetings in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. The conference is expected to attract worldwide gastroenterologists, clinical
investigators, scientists and medical professionals related to the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery.
“We are very pleased to be presenting the data from our IBD research program at the upcoming Digestive Disease
Week Conference”, said Christopher J. Moreau, CEO of Nash Pharmaceuticals. “It will be the first time that the Company will have an
opportunity to present its findings to the global IBD research community.”
About IBD
In a 2018 report by Visiongain, the Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028
shows that the global inflammatory bowel diseases (IBD) drug market is estimated at $6.7B in 2017 and $7.6B in 2023. Biologic
therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of
6.3% from 2018-2023.
About Nash Pharmaceuticals Inc.
Nash Pharmaceuticals Inc. is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash is a clinical
stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic
kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses
for existing drugs.
For more information, visit www.nashpharmaceuticals.com
CONTACT INFORMATION
Christopher J. Moreau
CEO
Nash Pharmaceuticals Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com
The CSE does not accept responsibility for the adequacy or accuracy of this
release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the
policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian
Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved
the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the
adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar
expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements
contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in
this news release are made as of the date of this news release and the Company will update or revise publicly any of the included
forward-looking statements as expressly required by applicable law.
